Skip to content

+1 877 566 4981

info@fdamap.com

Icon-instagram-1 X-twitter Icon-facebook Icon-linkedin
  • Home
  • About
    • About FDA Map
    • Leadership
    • Testimonials
  • Training
    • Webinars
    • Workshops
    • Custom Training
  • Services
    • Clinical Trial
    • Regulatory Services
    • Project Management
    • FDA Auditing
    • IND Submission
    • NDA Submission
    • 510(k) Submission
    • Quality Assurance
    • Site Certification
  • Insights
    • Blog
    • Articles
    • Press Releases
    • Resources
  • Contact Us
Contact Us
  • Home
  • About
    • About FDA Map
    • Leadership
    • Testimonials
  • Training
    • Webinars
    • Workshops
    • Custom Training
  • Services
    • Clinical Trial
    • Regulatory Services
    • Project Management
    • FDA Auditing
    • IND Submission
    • NDA Submission
    • 510(k) Submission
    • Quality Assurance
    • Site Certification
  • Insights
    • Blog
    • Articles
    • Press Releases
    • Resources
  • Contact Us

Day: June 20, 2019

Alexa To Detect Cardiac Arrest: Software-based Diagnostics In Every Home 

April 22, 2025June 20, 2019 by Prahsant Kumar

A study released this week reported that common home-based smart listening devices like Amazon Echo and iPhones could be used to detect cardiac arrest based on irregular breathing sound. The authors show how everyday common devices can be used not only to detect cardiac arrest with a greater than 97% sensitivity and specificity but that … Read more

Categories Blog

FDA’s Enforcement Discretion on CBD Creates Confusion for Consumers 

April 22, 2025June 20, 2019 by Prahsant Kumar

FDA has maintained officially that cannabidiol (CBD) is regulated as drug and hence it is illegal to add CBD to food and dietary supplement while at the same time letting thousands of CBD containing food and supplement products sells openly. CBD is the active ingredient of one FDA-approved drug, Epidiolex, but is available in thousands … Read more

Categories Blog

Recent Posts

  • From In silico to In vivo: Orchestrating AI for Breakthrough Therapeutics
  • Navigating the Hallucination Risks of Regulatory AI
  • Beyond the P-Value: Navigating the FDA’s New Bayesian Guidance for Drugs and Biologics
  • The Lean IND: Operationalizing the “Least Burdensome” Mandate
  • Beyond the LAL: Critical Updates to Bacterial Endotoxins and Pyrogen Testing

Recent Comments

No comments to show.

One-stop source for FDA consultation, regulatory affairs training, and clinical trial services.

Icon-instagram-1 X-twitter Icon-facebook Icon-linkedin

Services

  • Webinars
  • Workshops
  • On-Demand Webinars
  • Custom training
  • Training Subscriptions

Company

  • About Us
  • Our Client
  • Testimonials
  • Free Resources
  • Newsletter

Support

  • Contact Us
  • Terms of Service
  • Privacy Policy

Payment Method

100% Secure Transaction

Copyright © 2025 FDAMap.com. All rights reserved.